Image source: The Motley Fool.
CymaBay Therapeutics Inc. (NASDAQ: CBAY)
Q3 2020 Earnings Call
Nov 05, 2020 , 4:30 p.m. ET
Operator
For further details see:
CymaBay Therapeutics Inc. (CBAY) Q3 2020 Earnings Call TranscriptImage source: The Motley Fool.
CymaBay Therapeutics Inc. (NASDAQ: CBAY)
Q3 2020 Earnings Call
Nov 05, 2020 , 4:30 p.m. ET
Operator
For further details see:
CymaBay Therapeutics Inc. (CBAY) Q3 2020 Earnings Call TranscriptMarket Wire News is a media platform, the information on this page was provided by Motley Fool via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
Gilead Sciences Inc’s (NASDAQ:GILD) executive revealed the company’s plans to increase its production of cell therapy cancer treat...